<DOC>
	<DOC>NCT00939783</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.</brief_summary>
	<brief_title>An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease</brief_title>
	<detailed_description>This study was terminated on May 7, 2010 as part of modification of the dimebon development plan following lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well -tolerated in clinical trials. Demonstration of efficacy for dimebon in Alzheimer's disease is pending completion of the ongoing DIM18 (CONCERT) Study.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Completion of previous Phase 3 Dimebon study (B1451027). Have any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>